glp 1 dangers π¨ As GLP-1 Use Explodes, Long-Term Safety Questions Are Growing Too From pancreatitis and gallbladder disease to rare liver safety concerns, experts say the rapid expansion of GLP-1 drugs like semaglutide and GLP-1 Medications: Everything You Need
Description
Personalization of Treatment to BMI and ORC Patient heterogeneity, including metabolically obese normal weight (MONW) individuals, patients with severe obesity (BMI 40), and sarcopenic elderly populations poses challenges for standardized interventions

In 2017, the Ozempic injection was approved by the U.S

JBMR Plus

Do not be one of them

We performed a systematic review and network meta-analysis to evaluate and compare GLP-1RAs efficacy in glycaemic control, weight management, and lipid profile in patients with type 2 diabetes

Other Extra-Pancreatic Sites of GLP-1R Expression The vast range of extra-pancreatic effects exerted by GLP-1 RAs (Figure 2) may be due to the combination of multiple activated intracellular signalling pathways and the breadth of GLP-1R expression across the human body